To evaluate the safety and efficacy of Thulasi ennai for the treatment of soolikanam(Bronchial asthma in children)

Phase -II,Non-randomized, Open label,single arm study on Siddha medicine Thulasi ennai in the treatment of soolikanam(childhood bronchial asthma) among 6-12 years of age. - THULASI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/11/022130

Enrollment

Registered

2019-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: THULASI ENNAI: Study participants with age group 6-12 years with bronchial asthma will be recruited as per protocol.The Siddha drug Thulasi ennai will be administer Intervention2: Thula

Eligibility

Inclusion criteria

Inclusion criteria: Cough without expectoration Dyspnoea Running nose chest tightness wheezing

Exclusion criteria

Exclusion criteria: Primary complex Hypersensitivity pneumonitis Lung abscess Cystic fibrosis Bronchiolitis

Design outcomes

Primary

Measure	Time frame
To evaluate the therapeutic efficacy of the Siddha herbal medicineTHULASI ENNAIin the treatment of SoolikanamTimepoint: The efficacy of the drug in pediatric bronchial asthma in 6-12 year age group	—

Secondary

Measure	Time frame
To assess and compare the symptoms before and after treatmentTimepoint: compare before and after treatment	—

Countries

India

Contacts

Public ContactS Sonitha

Government Siddha medical college,Chennai

ranimoorthybsms19@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026